Antiplatelet therapy: glycoprotein IIb/IIIa receptor antagonists
Kessler, S.; Kessler, D.; Frishman, W.H.
Drugs of Today 35(6): 413-418
1999
ISSN/ISBN: 1699-3993 PMID: 12973387 Document Number: 510078
The glycoprotein IIb/IIIa antagonists are potent drugs that inhibit platelet aggregation. They are formulated as monoclonal antibodies and synthetic peptides for intravenous use in patients undergoing high-risk angioplasty procedures and in patients with unstable coronary syndromes. Orally active agents are now being evaluated in clinical trials.
Document emailed within 1 workday
Related Documents
Singh, S.; Gopal, A.K.; Bahl, V.K. 2005: Glycoprotein IIb/IIIa receptor antagonists: are we ignoring the evidence Indian Heart Journal 57(3): 201-209Kondo, K. 2000: Investigational new drugs among glycoprotein IIb/IIIa-receptor antagonists Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 116(5): 263-268
Moliterno, D.J.; Topol, E.J. 1997: Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction Thrombosis and Haemostasis 78(1): 214-219
Konstantopoulos, K.; Mousa, S.A. 2001: Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond Current Opinion in Investigational Drugs 2(8): 1086-1092
Zimarino, M.; De Caterina, R. 2004: Glycoprotein IIb-IIIa antagonists in non-ST elevation acute coronary syndromes and percutaneous interventions: from pharmacology to individual patient's therapy: part 1: the evidence of benefit Journal of Cardiovascular Pharmacology 43(3): 325-332
Hostetter, J.C.; Bhatt, D.L. 2003: The expanding role of antiplatelet agents in coronary artery disease. a current review of aspirin, glycoprotein IIb/IIIa inhibitors, and the thienopyridines Minerva Cardioangiologica 51(5): 531-546
Gambhir, D.S.; Mukhopadhyay, S. 2000: Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary interventions Indian Heart Journal 52(5): 524-532
Rasmussen, L.H.; Husted, S.E.; Clemmensen, P.M.; Gøtzsche, C.O.; Helqvist, S.; Kristensen, S.D.; Pedersen, K.E.; Rasmussen, K.; Rasmussen, S. 2000: Clinical studies on glycoprotein IIb/IIIa receptor antagonist Ugeskrift for Laeger 162(44): 5944-5947
Cervinka, P. 1998: Clinical use of glycoprotein IIb/IIIa receptor blockers in invasive cardiology Vnitrni Lekarstvi 44(7): 439-443
Decalf, V.; Sabbah, L.; Lafont, A.; Danchin, N.; Durand, E. 2007: Gp IIb/IIIa receptor antagonists in acute coronary syndromes with no ST elevation Archives des Maladies du Coeur et des Vaisseaux 100(12): 1006-1012
Coller, B.S.; Lang, D.; Scudder, L.E. 1997: Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade Circulation 95(4): 860-867
Coto, H. 2000: Platelet receptor glycoprotein IIb/IIIa inhibition with eptifibatide in a patient with thrombocytopenia after treatment with abciximab Journal of Invasive Cardiology 12(10): 528-531
Cook, N.S.; Bruttger, O.; Pally, C.; Hagenbach, A. 1993: The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active Thrombosis and Haemostasis 70(5): 838-847
Rerkpattanapipat, P.; Kotler, M.N.; Yazdanfar, S. 1999: Images in cardiovascular medicine. Rapid dissolution of massive intracoronary thrombosis with platelet glycoprotein IIb/IIIa receptor inhibitor Circulation 99(22): 2965
White, H.D. 2000: Low-molecular-weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies? Journal of Invasive Cardiology 12 Suppl A: 6a
Ottani, F.; Bresciani, B.; La Vecchia, L.; Favero, L.; Fontanelli, A.; Galvani, M. 2002: Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis Italian Heart Journal. Suppl: Official Journal of the Italian Federation of Cardiology 3(5): 544-554
Nishida, M.; Matsuno, H.; Kozawa, O.; Ueshima, S.; Matsuo, O.; Collen, D.; Uematsu, T. 2000: tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitor Journal of Cardiovascular Pharmacology 36(6): 770-775
Abu-Amero, K.K.; Wyngaard, C.A.; Dzimiri, N. 2004: Association of the platelet glycoprotein receptor IIIa (PlA1/PlA1) genotype with coronary artery disease in Arabs Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 15(1): 77-79
Franzosi, M.G. 2001: Reperfusion after acute myocardial infarct with fibrinolytic therapy o combination reduced fibrinolytic therapy and a glycoprotein IIb/IIIa inhibitor: the GUSTO V study Italian Heart Journal. Suppl: Official Journal of the Italian Federation of Cardiology 2(9): 1034-1036
Rübsamen, K.; Hornberger, W.; Kirchengast, M. 1995: Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein 11b/IIIa-receptor antagonist Ro 43-8857 Thrombosis and Haemostasis 74(5): 1353-1360